# E1505

## For Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer

### Treatment Plan

**Arm A:**
- Chemotherapy*
- 4 21-day cycles

**Arm B:**
- Chemotherapy*
- Bevacizumab 15mg/kg IV Day 1 either before or after chemotherapy
- 4 21-day cycles
- Bevacizumab will then continue for up to a total of one year (q 21 days)

*Chemotherapy Options—Must be selected prior to randomization
- Vinorelbine 30 mg/m² IV Days 1 and 8
- Cisplatin 75 mg/m² IV Day 1
- Docetaxel 75 mg/m² IV Day 1
- Cisplatin 75 mg/m² IV Day 1
- Gemcitabine 1200 mg/m² IV Days 1 and 8
- Cisplatin 75 mg/m² IV Day 1
- Pemetrexed 500 mg/m² IV Day 1
- Cisplatin 75 mg/m² IV Day 1

*(this regimen only for patients with non-squamous histology)*

### Patient Population

See Section 3.0 for Full Eligibility Details

- Patients must have undergone complete resection of their NSCLC (stage IB [≥ 4 cm] - IIIA [T2-3N0, T1-3N1, T1-3N2]) prior to enrollment.
- Patients must have had lobectomy, sleeve lobectomy, bi-lobectomy, or pneumonectomy. Mediastinal LN sampling must have been done at time of pre-operative mediastinoscopy or intraoperatively.
- Patients must be ≥ 6 weeks (42 days) and ≤ 12 weeks (84 days) post-thoracotomy.
- Patients must not have received prior systemic chemotherapy at any time (see Section 3.6.1 for exceptions for non-malignant indications), or hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years of randomization.
- Patients must not have any history of CVA or TIA; no symptomatic or uncontrolled CHF or cardiac arrhythmia.
- Patients with known history of MI or other evidence of thrombotic disease (angina) must have no evidence of active disease within at least 12 months prior to randomization.

**Number of Participants:** 1500

### Patient Enrollment

All Sites: Oncology Patient Enrollment Network (OPEN) [https://open.ctsu.org/open](https://open.ctsu.org/open)

**Protocol Information**

CTSU Help Desk: 1-888-823-5923, CTSUcontact@westat.com, www.ctsu.org

Please Enroll Your Eligible Patients!
**ECOG 1505**

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

**Schema**

Arm A - 1 of 4 chemotherapy regimens, no bevacizumab

Arm B - 1 of 4 chemotherapy regimens, plus bevacizumab

Bevacizumab, 15 mg/kg IV/6

First 4 cycles - Day 1, delivered immediately prior to chemotherapy administration or immediately after completion of chemotherapy at physician’s discretion.

Then, continue every 2 weeks for up to 1 year measured from date of first day of protocol treatment.

Chemotherapy will be given until disease progression, unacceptable toxicity or a total of 4 cycles.

Chemotherapy will be given for up to 1 year (measured from first day of protocol treatment).